Patent · US Active

Treatment for multiple myeloma (MM)

US11591406B2 · kind B2 · utility

0Cited by

5References

7Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stephane Leclair · Gauting, DE
Jan Endell · Munich, DE
Stefan Härtle · Jesenwang, DE

Key dates

Filing date	Nov 25, 2019
Grant date	Feb 28, 2023
Priority date	—
Expiry date	Apr 29, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/21
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.